Enliven Therapeutics, Inc.
ELVN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$20,148 | -$25,335 | -$28,544 | -$23,180 |
| Dep. & Amort. | $62 | $154 | $74 | $80 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $7,724 | $6,799 | $5,339 |
| Change in WC | -$157 | $313 | -$2,496 | -$510 |
| Other Non-Cash | $6,964 | $87 | $40 | $1,068 |
| Operating Cash Flow | -$13,279 | -$17,057 | -$24,127 | -$17,203 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $1 | -$139 | -$20 | $0 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$71,860 | -$240,186 | -$59,225 | -$116,515 |
| Inv. Sales/Matur. | $67,801 | $56,736 | $60,672 | $117,242 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$4,058 | -$183,589 | $1,427 | $727 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | -$368 | $218,378 | $234 | -$50,507 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $90,479 |
| Financing Cash Flow | -$368 | $218,378 | $234 | $39,972 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$17,705 | $17,732 | -$22,466 | $23,496 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $119,437 | $101,705 | $124,171 | $100,675 |
| End Cash | $101,732 | $119,437 | $101,705 | $124,171 |
| Free Cash Flow | -$13,278 | -$17,196 | -$24,147 | -$17,203 |